Skip to main content

Fiscal Wizard · Single-issue tearsheet

OTLK / Jun 21, 2026 Run #7359

OTLK

Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Composite verdict

F 14.6 / 100
Gated stand-aside 0 drivers · 6 gates blocking
Stand aside Setup or conviction grade does not support a directional trade.

Industry rank 361st of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: volatile range

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

14.6 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Cash Conversion Cycle 100
Return on Assets 0
EPS Growth (YoY) 100
Free Cash Flow Yield 0
Revenue Growth (YoY) 0

Technicals Unscored

/ 100

Stand aside — active guards gated the directional signals that fired. · 43 signals shown.

Risk Gates

6 blocking 6 caution

6 guards active, 42 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for OTLK.